Sutro Biopharma Total Liabilities 2017-2022 | STRO

Sutro Biopharma total liabilities from 2017 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Sutro Biopharma Annual Total Liabilities
(Millions of US $)
2021 $89
2020 $62
2019 $59
2018 $92
2017 $47
2016 $58
Sutro Biopharma Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $83
2021-12-31 $89
2021-09-30 $88
2021-06-30 $52
2021-03-31 $51
2020-12-31 $62
2020-09-30 $63
2020-06-30 $71
2020-03-31 $72
2019-12-31 $59
2019-09-30 $62
2019-06-30 $69
2019-03-31 $72
2018-12-31 $92
2018-09-30 $99
2018-06-30 $0
2018-03-31 $0
2017-12-31
2017-09-30 $0
2016-12-31 $58
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.203B $0.062B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00